Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriela Hobbs

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela Hobbs
Hematology. American Society of Hematology. Education Program|December 7, 2024
Pregnancy: MPN management before, during, and after pregnancyJoan How, Gabriela Hobbs
Current Hematologic Malignancy Reports|September 3, 2021
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela Hobbs
Cancers|July 26, 2020
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the LiteratureJoan How, Gabriela Hobbs
Current Hematologic Malignancy Reports|October 14, 2021
Future Directions in Chronic Phase CML TreatmentNathalie Javidi-Sharifi, Gabriela Hobbs
Current Hematologic Malignancy Reports|April 25, 2018
Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-makingJames A Kennedy, Gabriela Hobbs
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 7, 2023
Anxiety exacerbation in a patient with chronic myeloid leukemia receiving dasatinib and venlafaxineChristopher Bell, Jessie Signorelli, Gabriela Hobbs
Current Opinion in Hematology|January 7, 2020
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasmsSam Sadigh, Robert P Hasserjian, Gabriela Hobbs
JACC. Cardiooncology|July 12, 2022
Cardiovascular Disease in Myeloproliferative Neoplasms: <i>JACC: CardioOncology</i> State-of-the-Art ReviewOrly Leiva, Gabriela Hobbs, Katya Ravid, et al.
Atherosclerosis|December 19, 2024
Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasmsOrly Leiva, Sophia Zhou, Joan How, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela Hobbs
Hematology. American Society of Hematology. Education Program|December 7, 2024
Pregnancy: MPN management before, during, and after pregnancyJoan How, Gabriela Hobbs
Current Hematologic Malignancy Reports|September 3, 2021
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela Hobbs
Cancers|July 26, 2020
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the LiteratureJoan How, Gabriela Hobbs
Current Hematologic Malignancy Reports|October 14, 2021
Future Directions in Chronic Phase CML TreatmentNathalie Javidi-Sharifi, Gabriela Hobbs
Current Hematologic Malignancy Reports|April 25, 2018
Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-makingJames A Kennedy, Gabriela Hobbs
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 7, 2023
Anxiety exacerbation in a patient with chronic myeloid leukemia receiving dasatinib and venlafaxineChristopher Bell, Jessie Signorelli, Gabriela Hobbs
Current Opinion in Hematology|January 7, 2020
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasmsSam Sadigh, Robert P Hasserjian, Gabriela Hobbs
JACC. Cardiooncology|July 12, 2022
Cardiovascular Disease in Myeloproliferative Neoplasms: <i>JACC: CardioOncology</i> State-of-the-Art ReviewOrly Leiva, Gabriela Hobbs, Katya Ravid, et al.
Atherosclerosis|December 19, 2024
Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasmsOrly Leiva, Sophia Zhou, Joan How, et al.
Pageof 6